Skip to main content

High Prevalence of Cancer and R&D in Fibrosarcoma to Augment Growth of Fibrosarcoma Drugs Market

 


A fibrosarcoma is an inflamed (malignant) tumor that originates from the connective fibrous tissue located at the ends of the bones of the lower arm or leg and then proceeds to spread to other surrounding tissues, causing extreme pain and complications. It's a form of cancer that typically grows slowly over an extended period of time. Fibrosarcoma may develop for several reasons, including: primary tumors at the facial prominences on one or both sides of the heart; fibrosarcoma may develop in response to an infection (such as those that occur in the stomach or esophagus); tumors may also develop on other areas of the body other than the skin. If you have any of these symptoms, you should contact your physician immediately. However, since the symptoms of fibrosarcoma are similar to those of other diseases, and because it's difficult to determine whether a disease exists, most people with fibrosarcoma are sent for check-ups each year.

Market Dynamics

High prevalence of cancer is expected to propel growth of the fibrosarcoma drugs market. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S. Moreover, increasing funding in cancer R&D is also expected to aid in growth of the fibrosarcoma drugs market. For instance, according to the National Cancer Research Institute (NCRI), cancer research funding by NCRI partners reached around US$ 750 million in 2018/19.   

R&D in fibrosarcoma is expected to offer lucrative growth opportunities for players in the fibrosarcoma drugs market. For instance, in January 2021, researchers from Children's Hospital of Philadelphia reported that neurotrophic tyrosine receptor kinase (NTRK) fusions are more common in pediatric tumors and also involve a wider range of tumors than adult cancers, information that could help prioritize screening for NTRK fusions in pediatric cancer patients who might benefit from treatment with TRK inhibitors.

Competitive Analysis

Major players operating in fibrosarcoma drugs market include, Cadila Healthcare Limited, Bristol-Myers Squibb Company, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Baxter International Inc., Eli Lilly and Company, Cullgen Inc., Pfizer limited, Johnson & Johnson., and Celon Laboratories Pvt. Ltd.

Major players operating in fibrosarcoma drugs market are focused on R&D to expand their product portfolio. For instance, in October 2020, Cullgen Inc. announced that the company’s internal program to develop selective degraders that target key proteins within the TRK family has been published by the Journal of Medicinal Chemistry.

 

Labels:

Comments

Post a Comment

Popular posts from this blog

Virology Testing Market Detailed In New Research Report 2023

  Virology testing consist of diagnostic methods that help in early detection of the disease such as hepatitis, influenza, HIV, sexually transmitted disease, RCV, and other viral associated disease. Virology testing examines for detection of viral antigens, nucleic acids, and antibodies in the given sample in order to confirm the presence of particular viral infection. There are more than 100 viral diseases identified. Virology Testing Market- Market Dynamics Virology testing market is projected to witness significant growth during forecast period with rising prevalence of virus originated diseases such as flu, hepatitis, AIDS, and STDs, Ebola, Influenza based viral infections, severe acute respiratory syndrome from coronavirus, hemorrhagic fever etc. across world. Early and fast diagnosis of virus infection is very essential to start treatment course. According to the World Health Organization (WHO), January 2018 factsheet, all types of influenza in combination causes annual...
Post a Comment
Read more

Epidermolysis Bullosa Therapeutics Market Is Booming Worldwide 2023-2028

  Epidermolysis bullosa is a group of rare inherited skin disorders that causes the skin to become very fragile. Any trauma or friction to the skin can cause painful blisters. The symptoms of epidermolysis bullosa include skin that blisters easily, blisters on hands and soles of the feet, thickened skin that may be scarred or change color over time, and thickening of the skin and nails. There are three types of epidermolysis bullosa which includes: ·          Epidermolysis bullosa simplex (EBS) – the most common type, which can range from mild, with a low risk of serious complications to severe ·          Dystrophic epidermolysis bullosa (DEB) – which can range from mild to severe ·          Junctional epidermolysis bullosa (JEB) – a rare form of epidermolysis bullosa that ranges from moderate to severe The type reflects where on the body the blistering ...
Post a Comment
Read more

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Analysis

  A primary driver for this market is the worldwide increase in occurrence of diabetes and cancer, across all age groups. According to the World Health Organization (WHO) 2018 statistics, the number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014. Moreover according to the World Health Organization cancer factsheet 2018, Cancer is the second leading cause of death globally, and is responsible for an estimated 9.6 million deaths in 2018.  Furthermore, increasing old age population is another driver, which is anticipated to create a high growth scenario for the market. As per the World Population Prospects 2019 revision, the number of people aged 80 years or over is projected to be triple, from 143 million in 2019 to 426 million in 2050. Alternatively, factors restraining the market are complications and risks associated with the treatment including diarrhea, nausea, hair loss, vomiting, severe infections, infertility, and heart complications....
Post a Comment
Read more